Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AG Monoclonal antibodies
L04AG06 Alemtuzumab
D02802 Alemtuzumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Central Nervous System Agents
Multiple Sclerosis Agents
Alemtuzumab
D02802 Alemtuzumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D02802 Alemtuzumab (USAN/INN); Alemtuzumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD52
D02802 Alemtuzumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02802
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02802